DongKoo Bio & Pharma Co. Ltd.
Abschluss
Cashflow
DongKoo Bio & Pharma Co. Ltd. (006620.KO) im Zahlenüberblick: Gewinn- und Verlustrechnung, Bilanz und Cashflow, wahlweise je Jahr oder Quartal. Im jüngsten Berichtszeitraum (Q1 26) lag „Operativer Cashflow" bei 10.397 Millionen KRW. Zeilen lassen sich per Häkchen als Diagramm vergleichen.
Alle Werte in Millionen KRW.
Zeilen ankreuzen und als Diagramm vergleichen (bis zu 4)
| Position | Q3 16 | Q4 16 | Q3 17 | Q4 17 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.534 | 737 | 2.951 | 215 | 7.632 | 10.139 | 1.500 | 6.520 | 7.209 | 7.489 | 3.944 | 8.072 | 15.131 | 2.772 | 3.589 | -161 | 4.128 | 16.819 | -1.608 | 410 | 2.415 | 760 | 6.214 | 2.366 | 18.218 | 17.344 | 195 | -10.825 | 1.197 | 5.146 | 10.397 | 5.915 | |
| 554 | 590 | 562 | 519 | 2.480 | 3.467 | 1.011 | 2.065 | 3.179 | 4.341 | 1.168 | 2.380 | 3.627 | 1.295 | 1.358 | 1.388 | 1.430 | 5.494 | 1.388 | 2.884 | 1.526 | 1.547 | 1.463 | 1.723 | 4.510 | 6.310 | 1.832 | 2.345 | 2.221 | 2.183 | 1.944 | 8.693 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 3,2 | 73 | 74 | 74 | 73 | 43 | 68 | 68 | 65 | 35 | 36 | 57 | 42 | 170 | |
| 1.817 | -2.226 | 987 | 434 | – | – | – | – | – | – | – | – | – | 819 | 2.124 | 2.796 | 1.144 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -2.054 | -2.444 | -3.252 | -6.144 | -7.638 | -1.250 | -426 | 2.103 | 818 | -3.148 | -8.841 | -11.567 | -7.072 | -6.251 | -10.326 | -2.188 | -4.991 | -1.848 | -886 | -4.366 | -6.228 | -4.834 | -12.654 | -1.503 | 6.045 | 8.240 | 129 | |
| 3.831 | 992 | 228 | 145 | 6.601 | 8.770 | 1.193 | 2.545 | 3.776 | 5.461 | 2.604 | 4.068 | 4.626 | 560 | 1.099 | 1.950 | 721 | 11.075 | 1.474 | 4.632 | 4.986 | 6.348 | 12.768 | 5.293 | 23.621 | 25.465 | 4.100 | 482 | 3.663 | 12.208 | 1.735 | 18.088 | |
| -801 | 1.066 | 582 | -1.463 | -4.909 | -11.225 | -198 | 8.319 | -8.078 | -12.564 | -916 | 5.510 | 3.061 | -2.597 | -9.830 | 1.805 | -2.800 | -27.014 | -1.612 | 1.965 | – | – | – | – | -36.478 | -45.033 | -12.489 | – | – | – | – | – | |
| – | – | – | – | – | – | – | 943 | 943 | 943 | – | 943 | 943 | 0,0 | 2.804 | 2.804 | 2.804 | 2.804 | – | 3.038 | 0,0 | 0,0 | – | – | 3.313 | 3.313 | – | – | 0,0 | 0,0 | – | – | |
| – | – | – | – | -1.937 | -1.998 | – | – | – | – | – | – | – | -1.998 | -1.671 | -2.463 | -2.995 | -2.995 | – | – | – | – | -440 | -1.479 | -2.999 | -3.408 | – | – | – | – | – | – | |
| -2.877 | -2.471 | -474 | -937 | – | – | – | – | – | – | – | – | – | -149 | -219 | 9.766 | -237 | – | – | – | – | – | – | – | 6.148 | 11.401 | 10.455 | 161 | 10.717 | 21.871 | -907 | 31.842 | |
| -2.877 | -2.471 | -474 | -937 | -968 | 6.715 | -262 | -1.505 | -2.196 | -361 | -155 | -1.256 | -1.465 | -2.223 | -1.890 | 6.120 | -769 | 3.185 | -221 | -1.037 | – | – | – | – | 26.451 | 37.194 | 10.207 | – | – | – | – | – | |
| 856 | -667 | 3.059 | -2.185 | 1.755 | 5.610 | 1.087 | 13.333 | -3.078 | -5.460 | 2.894 | 12.342 | 16.765 | -2.089 | -8.127 | 7.781 | 585 | -7.043 | -3.441 | 1.350 | -4.051 | 5.900 | -4.440 | 918 | 8.116 | 9.660 | -2.141 | -17.676 | 5.466 | 10.539 | 1.176 | -495 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 5.430 | -3.082 | -1.140 | -2.571 | -5.588 | -6.554 | -2.927 | 4.077 | -2.717 | -3.904 | -11.306 | -2.466 | -7.062 | 8.662 | -12.173 |
LTM = letzte zwölf Monate (Summe der jüngsten vier Quartale).
Datenstand: 14. August 2026 · Quelle: Fundamentaldaten & SEC-Berichte (Geschäfts- und Quartalsberichte, 10-K/10-Q)
Hinweis: reine Faktenanalyse, keine Anlageberatung und keine Aufforderung zum Kauf oder Verkauf. Angaben ohne Gewähr.